Conceptual clarifications regarding Chilean Act 20850 on public funding of high-cost diseases

Area of Science:

• Medical Law
• Clinical Research Ethics
• Public Health Policy

Background:

• Chile's 20850 law (2015) allocates public funds for rare and costly diseases.
• The law amends regulations for human research, enhancing subject protection.
• Ambiguous phrasing led to debate regarding the scope of protective measures in clinical research.

Purpose of the Study:

• To clarify the application of Chile's 20850 law concerning clinical research.
• To distinguish between compassionate use and phase I/II therapeutic trials.
• To emphasize ethical obligations for post-trial medication benefits.

Main Methods:

• Legal analysis of Chile's Law 20850 and its amendments to the Sanitary Code.
• Contextual interpretation of the law's provisions regarding human research subjects.
• Review of ethical principles governing therapeutic trials for rare diseases.

Main Results:

• The law's protective measures, including post-investigational benefits and insurance, primarily apply to phase I therapeutic trials.
• A clear distinction is drawn between compassionate use and genuine phase I/II trials for orphan diseases.
• The ethical imperative for providing beneficial medication post-trial is highlighted.

Conclusions:

• Chile's 20850 law provides crucial protections for participants in early-phase therapeutic trials for rare diseases.
• Understanding the law's specific application avoids misinterpretation regarding broader clinical research.
• Ensuring continued medical benefits is an ethical and medical necessity for patients in these trials.